BioCentury | Jan 12, 2017
Clinical News

Onapristone: Ph II halted

...is evaluating all development, strategic or corporate opportunities available for onapristone, AR-42 and AR-12 . AR-42...
BioCentury | Jun 18, 2012
Clinical News

AR-42 regulatory update

...The European Commission granted Orphan Drug designation for Arno's AR-42 to treat meningioma and schwannoma. The...
...I/IIa testing to treat multiple myeloma (MM), chronic lymphocytic leukemia (CLL), lymphoma and solid tumors. AR-42...
...histone and non-histone proteins that regulate gene expression. Arno Therapeutics Inc. (OTCBB:ARNI), Parsippany, N.J. Product: AR-42...
BioCentury | May 21, 2012
Clinical News

AR-42 regulatory update

...Arno said the European Commission granted Orphan Drug designation for AR-42 to treat neurofibromatosis type 2...
...I/IIa testing to treat multiple myeloma (MM), chronic lymphocytic leukemia (CLL), lymphoma and solid tumors. AR-42...
...histone and non-histone proteins that regulate gene expression. Arno Therapeutics Inc. (OTCBB:ARNI), Parsippany, N.J. Product: AR-42...
BioCentury | Feb 27, 2012
Clinical News

AR-42 regulatory update

...FDA granted Orphan Drug designation for Arno's AR-42 to treat CNS tumors. The broad-spectrum deactylation inhibitor...
...chronic lymphocytic leukemia (CLL), lymphoma and solid tumors. Arno Therapeutics Inc. (OTCBB:ARNI), Parsippany, N.J. Product: AR-42...
BioCentury | Jun 28, 2010
Clinical News

AR-42: Phase I/IIa started

...to evaluate oral AR-42 in about 50 patients. Arno Therapeutics Inc. (Pink:ARNI), Pasippany, N.J. Product: AR-42...
BioCentury | Jun 9, 2008
Finance

Ebb & Flow

...cancers. In addition, the company hopes to submit INDs for preclinical oncology compounds AR-12 and AR-42...
BioCentury | Jun 9, 2008
Company News

Arno, Laurier International Inc. deal

...trials to treat solid tumors. The company also has two preclinical cancer compounds, AR-12 and AR-42...
Items per page:
1 - 7 of 7